thalidomide has been researched along with Stevens-Johnson Syndrome in 27 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Stevens-Johnson Syndrome: Rare cutaneous eruption characterized by extensive KERATINOCYTE apoptosis resulting in skin detachment with mucosal involvement. It is often provoked by the use of drugs (e.g., antibiotics and anticonvulsants) or associated with PNEUMONIA, MYCOPLASMA. It is considered a continuum of Toxic Epidermal Necrolysis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pomalidomide and dexamethasone is a standard of care for patients with multiple myeloma in whom bortezomib and lenalidomide treatment has failed." | 9.30 | Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. ( Avivi, I; Benyamini, N; Blacklock, H; Chanan-Khan, A; Farooqui, M; George, A; Goldschmidt, H; Iida, S; Jagannath, S; Kher, U; Larocca, A; Liao, J; Lonial, S; Marinello, P; Mateos, MV; Matsumoto, M; Ocio, EM; Oriol, A; Ribrag, V; Rodriguez-Otero, P; San Miguel, J; Schjesvold, F; Sherbenou, D; Simpson, D; Suzuki, K; Usmani, SZ, 2019) |
| " Here, we describe a patient with SJS while receiving lenalidomide in combination with prednisolone for treatment-naïve multiple myeloma." | 8.88 | Stevens-Johnson syndrome after lenalidomide therapy for multiple myeloma: a case report and a review of treatment options. ( Allegra, A; Alonci, A; Catena, S; D'Angelo, A; Gerace, D; Greve, B; Musolino, C; Penna, G; Russo, S, 2012) |
| " Lenalidomide is a derivative of thalidomide used in the treatment of multiple myeloma." | 7.77 | Possible lenalidomide-induced Stevens-Johnson syndrome during treatment for multiple myeloma. ( Bolesta, S; Boruah, PK; Shetty, SM, 2011) |
| "Primary myelofibrosis (PMF) is a chronic myeloproliferative neoplasm characterized by progressive anemia, massive splenomegaly, leukoerythroblastosis, extramedullary hematopoiesis and in about 50% of cases the presence of JAK2V617F mutation." | 5.35 | Toxic epidermal necrolysis in a patient with primary myelofibrosis receiving thalidomide therapy. ( Colagrande, M; Coletti, G; Di Ianni, M; Fargnoli, MC; Lapecorella, M; Moretti, L; Peris, K; Tabilio, A, 2009) |
| "Pomalidomide and dexamethasone is a standard of care for patients with multiple myeloma in whom bortezomib and lenalidomide treatment has failed." | 5.30 | Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. ( Avivi, I; Benyamini, N; Blacklock, H; Chanan-Khan, A; Farooqui, M; George, A; Goldschmidt, H; Iida, S; Jagannath, S; Kher, U; Larocca, A; Liao, J; Lonial, S; Marinello, P; Mateos, MV; Matsumoto, M; Ocio, EM; Oriol, A; Ribrag, V; Rodriguez-Otero, P; San Miguel, J; Schjesvold, F; Sherbenou, D; Simpson, D; Suzuki, K; Usmani, SZ, 2019) |
| " Here, we describe a patient with SJS while receiving lenalidomide in combination with prednisolone for treatment-naïve multiple myeloma." | 4.88 | Stevens-Johnson syndrome after lenalidomide therapy for multiple myeloma: a case report and a review of treatment options. ( Allegra, A; Alonci, A; Catena, S; D'Angelo, A; Gerace, D; Greve, B; Musolino, C; Penna, G; Russo, S, 2012) |
| " Although lenalidomide therapy was initiated, it had to be discontinued because of Stevens-Johnson syndrome, which occurred during the second course of treatment." | 3.79 | [A case in which chromosome 5q deletion syndrome resistant to lenalidomide therapy transformed to refractory anemia with excess blasts]. ( Abe, T; Arihara, Y; Fujii, S; Fujita, M; Hirako, T; Jomen, W; Kato, J; Kuroda, H; Maeda, M; Miura, S; Nagashima, K; Sakurai, T; Yamada, M; Yoshida, M, 2013) |
| " Lenalidomide is a derivative of thalidomide used in the treatment of multiple myeloma." | 3.77 | Possible lenalidomide-induced Stevens-Johnson syndrome during treatment for multiple myeloma. ( Bolesta, S; Boruah, PK; Shetty, SM, 2011) |
| " Although thalidomide-induced dermatologic disorders rarely were reported before thalidomide was administered to patients positive for the human immunodeficiency virus, hypersensitivity reactions including rash are the agent's major dose-limiting toxicities in this population." | 3.70 | Thalidomide-induced toxic epidermal necrolysis. ( Horowitz, SB; Stirling, AL, 1999) |
| "Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome are rare, severe cutaneous adverse reactions usually triggered by medications." | 2.82 | Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome. ( Beecker, J; Jacobsen, A; Langley, A; Mutter, E; Olabi, B; Pardo Pardo, J; Parker, R; Ramsay, T; Saavedra, A; Shelley, A; Stewart, F; Worley, B, 2022) |
| "Thalidomide is a potent inhibitor of TNF-alpha action." | 2.69 | Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. ( Bocquet, H; Boudeau, S; Brun-Buisson, C; Duguet, C; Latarjet, J; Maignan, M; Milpied, B; Pilorget, A; Revuz, J; Roujeau, JC; Schuhmacher, MH; Vaillant, L; Wolkenstein, P, 1998) |
| "Treatment with thalidomide was not shown to be effective and was associated with significantly higher mortality than placebo." | 2.41 | Interventions for toxic epidermal necrolysis. ( Majumdar, S; Mockenhaupt, M; Roujeau, J; Townshend, A, 2002) |
| "Primary myelofibrosis (PMF) is a chronic myeloproliferative neoplasm characterized by progressive anemia, massive splenomegaly, leukoerythroblastosis, extramedullary hematopoiesis and in about 50% of cases the presence of JAK2V617F mutation." | 1.35 | Toxic epidermal necrolysis in a patient with primary myelofibrosis receiving thalidomide therapy. ( Colagrande, M; Coletti, G; Di Ianni, M; Fargnoli, MC; Lapecorella, M; Moretti, L; Peris, K; Tabilio, A, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.70) | 18.7374 |
| 1990's | 4 (14.81) | 18.2507 |
| 2000's | 8 (29.63) | 29.6817 |
| 2010's | 12 (44.44) | 24.3611 |
| 2020's | 2 (7.41) | 2.80 |
| Authors | Studies |
|---|---|
| Jacobsen, A | 1 |
| Olabi, B | 1 |
| Langley, A | 1 |
| Beecker, J | 1 |
| Mutter, E | 1 |
| Shelley, A | 1 |
| Worley, B | 1 |
| Ramsay, T | 1 |
| Saavedra, A | 1 |
| Parker, R | 1 |
| Stewart, F | 1 |
| Pardo Pardo, J | 1 |
| Tsai, TY | 1 |
| Huang, IH | 1 |
| Chao, YC | 1 |
| Li, H | 1 |
| Hsieh, TS | 1 |
| Wang, HH | 1 |
| Huang, YT | 1 |
| Chen, CY | 1 |
| Cheng, YC | 1 |
| Kuo, PH | 1 |
| Huang, YC | 1 |
| Tu, YK | 1 |
| Kinoshita, Y | 1 |
| Saeki, H | 1 |
| Mateos, MV | 1 |
| Blacklock, H | 1 |
| Schjesvold, F | 1 |
| Oriol, A | 1 |
| Simpson, D | 1 |
| George, A | 1 |
| Goldschmidt, H | 1 |
| Larocca, A | 1 |
| Chanan-Khan, A | 1 |
| Sherbenou, D | 1 |
| Avivi, I | 1 |
| Benyamini, N | 1 |
| Iida, S | 1 |
| Matsumoto, M | 1 |
| Suzuki, K | 1 |
| Ribrag, V | 1 |
| Usmani, SZ | 1 |
| Jagannath, S | 1 |
| Ocio, EM | 1 |
| Rodriguez-Otero, P | 1 |
| San Miguel, J | 1 |
| Kher, U | 1 |
| Farooqui, M | 1 |
| Liao, J | 1 |
| Marinello, P | 1 |
| Lonial, S | 1 |
| Inoue, Y | 1 |
| Saito, T | 1 |
| Tsuruoka, Y | 1 |
| Sato, K | 1 |
| Nishio, Y | 1 |
| Suzuki, Y | 1 |
| Kato, M | 1 |
| Isobe, Y | 1 |
| Sakai, H | 1 |
| Takahashi, M | 1 |
| Miura, I | 1 |
| Yamada, M | 1 |
| Kuroda, H | 1 |
| Jomen, W | 1 |
| Yoshida, M | 1 |
| Miura, S | 1 |
| Abe, T | 1 |
| Sakurai, T | 1 |
| Fujii, S | 1 |
| Maeda, M | 1 |
| Fujita, M | 1 |
| Nagashima, K | 1 |
| Arihara, Y | 1 |
| Hirako, T | 1 |
| Kato, J | 1 |
| Hwang, S | 1 |
| Woo, Y | 1 |
| Kim, M | 1 |
| Park, HJ | 1 |
| Tebruegge, M | 1 |
| Pantazidou, A | 1 |
| Castaneda, CP | 1 |
| Brandenburg, NA | 1 |
| Bwire, R | 1 |
| Burton, GH | 1 |
| Zeldis, JB | 1 |
| Colagrande, M | 1 |
| Di Ianni, M | 1 |
| Coletti, G | 1 |
| Peris, K | 1 |
| Fargnoli, MC | 1 |
| Moretti, L | 1 |
| Lapecorella, M | 1 |
| Tabilio, A | 1 |
| Eo, WK | 1 |
| Kim, SH | 1 |
| Cheon, SH | 1 |
| Lee, SH | 1 |
| Jeong, JS | 1 |
| Kim, YS | 1 |
| Chang, HK | 1 |
| Suh, KS | 1 |
| Kim, HY | 1 |
| Wäsch, R | 1 |
| Jakob, T | 1 |
| Technau, K | 1 |
| Finke, J | 1 |
| Engelhardt, M | 1 |
| Allegra, A | 2 |
| Alonci, A | 2 |
| Penna, G | 1 |
| Russo, S | 2 |
| Gerace, D | 1 |
| Greve, B | 1 |
| D'Angelo, A | 1 |
| Catena, S | 2 |
| Musolino, C | 2 |
| Boruah, PK | 1 |
| Bolesta, S | 1 |
| Shetty, SM | 1 |
| Siniscalchi, A | 1 |
| Tendas, A | 1 |
| Morino, L | 1 |
| Dentamaro, T | 1 |
| De Bellis, A | 1 |
| Perrotti, A | 1 |
| de Fabritiis, P | 1 |
| Musto, P | 1 |
| Caravita, T | 1 |
| Rizzotti, P | 1 |
| Rotondo, F | 1 |
| Majumdar, S | 1 |
| Mockenhaupt, M | 1 |
| Roujeau, J | 1 |
| Townshend, A | 1 |
| Brun-Buisson, C | 2 |
| Vaishampayan, UN | 1 |
| Heilbrun, LK | 1 |
| Shields, AF | 1 |
| Lawhorn-Crews, J | 1 |
| Baranowski, K | 1 |
| Smith, D | 1 |
| Flaherty, LE | 1 |
| Namazi, MR | 1 |
| Wolkenstein, P | 1 |
| Latarjet, J | 1 |
| Roujeau, JC | 1 |
| Duguet, C | 1 |
| Boudeau, S | 1 |
| Vaillant, L | 1 |
| Maignan, M | 1 |
| Schuhmacher, MH | 1 |
| Milpied, B | 1 |
| Pilorget, A | 1 |
| Bocquet, H | 1 |
| Revuz, J | 1 |
| Klausner, JD | 1 |
| Kaplan, G | 1 |
| Haslett, PA | 1 |
| Levy, R | 1 |
| Horowitz, SB | 1 |
| Stirling, AL | 1 |
| Rajkumar, SV | 1 |
| Gertz, MA | 1 |
| Witzig, TE | 1 |
| Schrader, KE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (KEYNOTE 183)[NCT02576977] | Phase 3 | 251 participants (Actual) | Interventional | 2015-10-19 | Terminated (stopped due to The study was terminated early due to business reasons) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Disease control rate was the percentage of participants who achieved confirmed sCR, CR, VGPR, PR, minimal response (MR) or have demonstrated stable disease (SD) for at least 12 weeks prior to any evidence of progression. PD was development of or an increase in the size of bone lesions or soft tissue plasmacytomas. CR = negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND <5% plasmacytomas in the bone marrow; sCR=stringent complete response, CR as above PLUS normal serum FLC assay ratio and absence of clonal cells in bone marrow by immunohistochemistry/fluorescence; VGPR = serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component <100 mg/24 hr; PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to <200 mg/24 hours. The data cutoff date was July 9, 2018. (NCT02576977)
Timeframe: Up to approximately 30 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Pembrolizumab+Pomalidomide+Dexamethasone | 88.1 |
| Standard of Care (SOC) Pomalidomide+Dexamethasone | 84.8 |
ORR was defined as the percentage of the participants in the analysis population who achieved at least a partial response (stringent complete response [sCR]+complete response [CR]+very good partial response [VGPR]+partial response [PR]) according to the IMWG. CR = negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND <5% plasmacytomas in the bone marrow; sCR=stringent complete response, CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR = serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component <100 mg/24 hr; PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to <200 mg/24 hours. The database cutoff date was July 9, 2018. (NCT02576977)
Timeframe: Up to approximately 30 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Pembrolizumab+Pomalidomide+Dexamethasone | 37.3 |
| Standard of Care (SOC) Pomalidomide+Dexamethasone | 42.4 |
Overall survival is defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Median overall survival was calculated from the product-limit (Kaplan-Meier) method for censored data. The database cutoff date was August 3, 2020. (NCT02576977)
Timeframe: Up to approximately 54 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab+Pomalidomide+Dexamethasone | 21.0 |
| Standard of Care (SOC) Pomalidomide+Dexamethasone | 39.6 |
An adverse event was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study. Database cutoff was August 3, 2020. (NCT02576977)
Timeframe: Up to approximately 54 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab+Pomalidomide+Dexamethasone | 26 |
| Standard of Care (SOC) Pomalidomide+Dexamethasone | 10 |
An adverse event (AE) was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study. Database cutoff was August 3, 2020. (NCT02576977)
Timeframe: Up to approximately 54 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab+Pomalidomide+Dexamethasone | 122 |
| Standard of Care (SOC) Pomalidomide+Dexamethasone | 119 |
Progression free survival was defined as the time from randomization to the first documented disease progression, or death due to any cause, whichever occurred first. PFS was assessed by CAC blinded central review according to the IMWG criteria based on the development of new bone lesions or soft tissue plasmacytomas or on a definite increase in the size of existing bone lesions or soft tissue plasmacytomas. Median PFS was calculated from the product-limit (Kaplan-Meier) method for censored data. The database cutoff date was July 9, 2018. (NCT02576977)
Timeframe: Up to approximately 30 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab+Pomalidomide+Dexamethasone | 5.7 |
| Standard of Care (SOC) Pomalidomide+Dexamethasone | 7.4 |
6 reviews available for thalidomide and Stevens-Johnson Syndrome
| Article | Year |
|---|---|
Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome.
Topics: Acetylcysteine; Adrenal Cortex Hormones; Adult; Autoimmune Diseases; Child; Cyclosporine; Etanercept | 2022 |
Treating toxic epidermal necrolysis with systemic immunomodulating therapies: A systematic review and network meta-analysis.
Topics: Drug Therapy, Combination; Glucocorticoids; Humans; Immunoglobulins, Intravenous; Immunologic Factor | 2021 |
A Review of the Active Treatments for Toxic Epidermal Necrolysis.
Topics: Acetylcysteine; Cyclosporine; Etanercept; Glucocorticoids; Humans; Immunoglobulins, Intravenous; Imm | 2017 |
Stevens-Johnson syndrome after lenalidomide therapy for multiple myeloma: a case report and a review of treatment options.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Multiple Myeloma | 2012 |
Interventions for toxic epidermal necrolysis.
Topics: Dermatologic Agents; Humans; Randomized Controlled Trials as Topic; Stevens-Johnson Syndrome; Thalid | 2002 |
[DSMB. 2. The importance of an efficient DSMB: some examples of high-risk clinical trials].
Topics: Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Humans; Risk Factors; Stevens- | 2005 |
3 trials available for thalidomide and Stevens-Johnson Syndrome
| Article | Year |
|---|---|
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2019 |
Phase II trial of interferon and thalidomide in metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Carcino | 2007 |
Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis.
Topics: Adult; Aged; Cause of Death; Dermatologic Agents; Double-Blind Method; Female; Humans; Interleukin-6 | 1998 |
18 other studies available for thalidomide and Stevens-Johnson Syndrome
| Article | Year |
|---|---|
Recombinant thrombomodulin improved Stevens-Johnson syndrome with high serum high-mobility group-B1 DNA-binding protein induced by lenalidomide administered to treat multiple myeloma.
Topics: HMGB1 Protein; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recombinant Proteins; Stev | 2013 |
[A case in which chromosome 5q deletion syndrome resistant to lenalidomide therapy transformed to refractory anemia with excess blasts].
Topics: Aged, 80 and over; Anemia, Macrocytic; Chromosome Deletion; Chromosomes, Human, Pair 5; Fatal Outcom | 2013 |
Toxic epidermal necrolysis induced by thalidomide and dexamethasone treatment for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Interactions; Female; Humans; Mi | 2017 |
Images in HIV/AIDS. Stevens-Johnson syndrome associated with thalidomide treatment in HIV infection.
Topics: Adolescent; Anti-HIV Agents; HIV Infections; Humans; Male; Oral Ulcer; Stevens-Johnson Syndrome; Tha | 2008 |
Erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis in lenalidomide-treated patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Erythema Multiforme; Female; Humans; Lenalidomide; M | 2009 |
Toxic epidermal necrolysis in a patient with primary myelofibrosis receiving thalidomide therapy.
Topics: Aged; Humans; Male; Neovascularization, Pathologic; Primary Myelofibrosis; Stevens-Johnson Syndrome; | 2009 |
Toxic epidermal necrolysis following thalidomide and dexamethasone treatment for multiple myeloma: a case report.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Dexamethasone; | 2010 |
Lenalidomide: Stevens-Johnson syndrome.
Topics: Antineoplastic Agents; Humans; Lenalidomide; Stevens-Johnson Syndrome; Thalidomide | 2010 |
Stevens-Johnson/toxic epidermal necrolysis overlap syndrome following lenalidomide treatment for multiple myeloma relapse after allogeneic transplantation.
Topics: Antineoplastic Agents; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Recurrence; Stevens-John | 2012 |
Possible lenalidomide-induced Stevens-Johnson syndrome during treatment for multiple myeloma.
Topics: Aged; Antineoplastic Agents; Female; Humans; Lenalidomide; Multiple Myeloma; Stevens-Johnson Syndrom | 2011 |
Lenalidomide cutaneous adverse event: a case of Stevens-Johnson syndrome (SJS) in a primary plasma cell leukaemia patient treated with lenalidomide and dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Eruptions; Humans; Lenalidomide; | 2012 |
Long-term complete remission in a multiple myeloma patient after Stevens-Johnson syndrome due to lenalidomide therapy.
Topics: Aged; Female; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Stevens-Johnson Syndrome; | 2013 |
Increased mortality in toxic epidermal necrolysis with thalidomide: corroborating or exonerating the pathogenetic role of TNF-alpha?
Topics: Humans; Immunosuppressive Agents; Stevens-Johnson Syndrome; Thalidomide; Tumor Necrosis Factor-alpha | 2006 |
Thalidomide in toxic epidermal necrolysis.
Topics: Dermatologic Agents; Humans; Immunosuppressive Agents; Stevens-Johnson Syndrome; Thalidomide | 1999 |
Thalidomide in toxic epidermal necrolysis.
Topics: Dermatologic Agents; fas Receptor; Humans; Immunosuppressive Agents; Receptors, Tumor Necrosis Facto | 1999 |
Thalidomide-induced toxic epidermal necrolysis.
Topics: Angiogenesis Inhibitors; Female; Glioblastoma; Humans; Hypersensitivity; Middle Aged; Stevens-Johnso | 1999 |
Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma.
Topics: Dexamethasone; Drug Interactions; Drug Therapy, Combination; Glucocorticoids; Humans; Male; Middle A | 2000 |
[Damages to the anterior eye segment by drugs].
Topics: Anti-Bacterial Agents; Anticoagulants; Antidepressive Agents; Cornea; Dinitrophenols; Drug-Related S | 1969 |